The Latest Cardiac and Vascular News
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement (“ASR”) to repurchase $500 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025. Under the terms of this ASR, Edwards will receive an […]
IRVINE, Calif., April 26, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2022. First Quarter Highlights and Outlook Q1 sales grew 10 percent to $1.34 billion; underlying1 13 percent Q1 TAVR sales grew 11 percent; underlying 14 percent Q1 EPS was $0.59; adjusted1 EPS was $0.60 Full year 2022 financial […]
IRVINE, Calif., Dec. 20, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced it received approval from the U.S. Food and Drug Administration (FDA) for the use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent (SAPIEN 3 with Alterra) for patients with severe pulmonary regurgitation. The Edwards SAPIEN 3 […]
